These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35634324)

  • 1. Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
    Chatterjee B; Thakur SS
    Front Immunol; 2022; 13():830990. PubMed ID: 35634324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
    N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
    Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
    SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
    Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
    Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
    Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
    Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
    Kokic G; Hillen HS; Tegunov D; Dienemann C; Seitz F; Schmitzova J; Farnung L; Siewert A; Höbartner C; Cramer P
    Nat Commun; 2021 Jan; 12(1):279. PubMed ID: 33436624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
    Das D; Mukhopadhyay P; Banerjee D
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19.
    Jiang Y; Yin W; Xu HE
    Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase.
    Naseem-Khan S; Berger MB; Leddin EM; Maghsoud Y; Cisneros GA
    J Chem Inf Model; 2022 May; 62(10):2456-2465. PubMed ID: 35435671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type.
    Mohammad A; Al-Mulla F; Wei DQ; Abubaker J
    Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
    Agoni C; Soliman MES
    Curr Pharm Biotechnol; 2021; 22(11):1520-1537. PubMed ID: 33109039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
    Banerjee A; Kanwar M; Maiti S
    Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
    Elfiky AA; Azzam EB; Shafaa MW
    Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
    Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
    Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.
    Zhang L; Zhang D; Wang X; Yuan C; Li Y; Jia X; Gao X; Yen HL; Cheung PP; Huang X
    Phys Chem Chem Phys; 2021 Mar; 23(10):5852-5863. PubMed ID: 33688867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
    Pirzada RH; Haseeb M; Batool M; Kim M; Choi S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33946869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.